Deamidated gliadin peptides


(Fusion protein of 4 deamidated gliadin peptides)

500 µg 735 € available

Art. No. G005
Synonym Deamidated Gliadin Peptide – fusion protein
Molecular Weight 33 kDa
Source Recombinantly produced in E. coli
Purity > 95% (SDS-PAGE and Coomassie staining)
Appearance White lyophilized solid.
Description DGPx4 is a fusion protein of 2 different deamidated gliadin peptides and 2 DQ2-epitopes, fused with a carrier protein to be used as antigen for the detection of antibodies specific for deamidated gliadin.
Reagents DGPx4 is lyophilized from a solution of ~50 mM NaH2PO4, pH 6.8.
Reconstitution Add at least the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be stored frozen in working aliquots.
Application The recombinant antigen is meant for solid (ELISA and immuno blot) and fluid phase diagnostic assays. The protein is bound by human type IgA and IgG (auto) antibodies.
Coating Dilute with your coating buffer to an appropriate concentration e.g. 1 μg/ml. Please notice that coating conditions have to be evaluated carefully.
Storage Store at -80°C.
If storage at -80°C is not possible, storage at ≤ -20°C is recommended. While no formal stability dataare available at -20°C, according to our overall experience stability is still given.
Store working aliquots preferably at -80°C(if not possible at ≤ -20°C, see comment above).
Avoid repeated freezing and thawing.
Delivery is possible at ambient temperature
Reference(s) Dørum S. et al., J Proteome Res. 2009; 8:1748-55
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.
Related Products G006 - DGPx2
G007 - DGPx1


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA